Mar 24, 2025 9:00am EDT Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
Mar 20, 2025 9:45am EDT Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market
Mar 19, 2025 9:00am EDT Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson
Mar 18, 2025 8:30am EDT Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient
Mar 03, 2025 6:00am EST Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits
Feb 18, 2025 7:00am EST Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson
Feb 10, 2025 7:10am EST Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25
Feb 05, 2025 7:00am EST Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025
Jan 27, 2025 7:00am EST US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug
Dec 30, 2024 7:00am EST Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson
